Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

STRO

S

Sutro Biopharma, Inc. (STRO)

NGM – Real vaqt narxi. Valyuta: USD

24.43

-0.48 (-1.93%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

24.43

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-month rally. STRO's pipeline centers on next-generation ADCs, with lead candidate STRO-004 in Phase 1 and key data expected mid-2026. Strategic partnerships, notably with Astellas, offer milestone potential, but past alliances (Ipsen, BMY, EMD Serono) have lapsed.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?

Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

10.02.2026

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.